A5088827025- Rheumatoid Arthritis Research and Therapies
- Inflammatory Bowel Disease
- Systemic Lupus Erythematosus Research
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Dermatology and Skin Diseases
- Autoimmune and Inflammatory Disorders Research
- Allergic Rhinitis and Sensitization
- Tuberculosis Research and Epidemiology
- Asthma and respiratory diseases
- Clinical practice guidelines implementation
- Monoclonal and Polyclonal Antibodies Research
- Contact Dermatitis and Allergies
- Colorectal Cancer Screening and Detection
- Cytomegalovirus and herpesvirus research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Venous Thromboembolism Diagnosis and Management
- Microscopic Colitis
- Cancer therapeutics and mechanisms
- Drug-Induced Adverse Reactions
- Lung Cancer Treatments and Mutations
- Global Healthcare and Medical Tourism
Pfizer (Japan)
2017-2023
Daiichi-Sankyo (Japan)
2011
Daiichi Sankyo (United States)
2011
Suzuki (Japan)
2011
Tokyo Medical and Dental University
2006
Atopic dermatitis (AD) negatively affects patients' daily lives. Poor medication adherence is a major barrier to treatment success. However, factors causing poor are unclear. This study aimed identify associated with improvement of in Japanese patients AD and evaluate illness burden unmet medical needs for AD. We retrospectively analyzed Web-based questionnaire surveys conducted 2018 aged 15 years above who had been in- or outpatients within the past year from survey. Quality life using...
Irinotecan-induced interstitial lung disease (ILD) requires accurate diagnosis, followed by prompt and appropriate treatment. This study was conducted to compile information imaging data define the characteristics of irinotecan-induced ILD. Searches were performed on collected for a drug reexamination application from spontaneous safety reports submitted Daiichi Sankyo Company, Limited. These database searches revealed 153 cases serious ILD that occurred in association with irinotecan...
Patients with ulcerative colitis (UC) are at an increased risk of certain infections and malignancies compared the general population. Incidence rates (IRs) hospitalized infections, herpes zoster (HZ), in patients UC, stratified by treatment, Japan were estimated.This retrospective study identified UC treated corticosteroids, immunosuppressants, or tumor necrosis factor inhibitors (TNFi) from 2 administrative databases (Japan Medical Data Center [JMDC] Vision [MDV]). IRs (unique events per...
<h3>Background</h3> Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety tofacitinib have been shown in patients (pts) with RA global Phase (P)2, P3 a long-term extension (LTE) study 2 P2 1 LTE Japanese pts. <h3>Objectives</h3> To evaluate following drug approval pts using all-case post-marketing surveillance (PMS) data. <h3>Methods</h3> An interim analysis (IA) data from ongoing 3 year PMS was conducted (5 Nov 2017 data-cut). All...
Objectives: To evaluate the real-world safety and effectiveness of etanercept (ETN) in Japanese patients with rheumatoid arthritis. Methods: This postmarketing surveillance study (NCT00503139) assessed ETN treatment over 3 2 years (from June 2007 to September 2011), respectively. Safety was evaluated by occurrence seriousness adverse drug reactions (ADRs), events (AEs) for malignancies. Effectiveness using Disease Activity Score 28 joints based on erythrocyte sedimentation rate (ESR) four...
<h3>Background</h3> Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety tofacitinib have been shown in RA patients global Phase 2, 3 (one study included Japanese patients) long-term extension (LTE) studies two 2 one LTE patients. <h3>Objectives</h3> We evaluated following drug approval with using all-case post-marketing surveillance (PMS) data. <h3>Methods</h3> A 6-month interim analysis data from ongoing 3-year PMS was conducted (5 Nov...
ABSTRACT Objectives We evaluated the real-world safety/effectiveness of tofacitinib, an oral Janus kinase inhibitor for treatment rheumatoid arthritis (RA), in patients with RA Japan registered a post-marketing surveillance study. Methods This interim analysis included data from July 2013 to December 2018. Adverse events (AEs), serious AEs (SAEs), Simplified Disease Activity Index (SDAI)/Clinical (CDAI)/Disease Score 28 joints, erythrocyte sedimentation rate [DAS28-4(ESR)] scores, and rates...
The prevalence of ulcerative colitis (UC) is increasing in Japan. Validated claims-based definitions are required to investigate the epidemiology UC and its treatment disease course clinical practice. This study aimed develop a algorithm for Japan.A committee epidemiologists, gastroenterologists, internal medicine physicians developed definition UC, based on diagnostic codes claims treatments, procedures (cytapheresis), or surgery (postoperative claims). Claims data medical records random...
Inflammatory bowel disease (IBD), which encompasses both ulcerative colitis (UC) and Crohn's (CD), is a risk factor for venous thromboembolism (VTE), includes deep vein thrombosis (DVT) pulmonary embolism (PE). To investigate the incidence of, factors for, VTE in patients with IBD Japan. This was retrospective, non-interventional study from Japan Medical Data Center claims database. Incidence rates (IRs; unique events per 100 patient‐years) were calculated VTE, DVT, PE among IBD, UC, CD...
Abstract Objectives This study was conducted to assess changes in the real‐world treatment of atopic dermatitis (AD) Japan. Methods Patients from JMDC Claims Database with ≥1 confirmed diagnosis AD, an identifiable medical care start date for and ≥2 AD–related treatments on separate dates between January 1, 2005, May 31, 2019, were included; data analyzed a yearly basis. Results In total, 411,102 patients included. The average age increased 12.0 18.8 years 2005 2017. any given year,...
Background: The risk of some types malignancy is increased in patients (pts) with rheumatoid arthritis (RA), compared the general population. We have previously reported incidence Japanese pts RA. 1-4 Objectives: This analysis further evaluated RA using recent data from large prospective observational study, IORRA. Methods: included all aged ≥18 years who were enrolled IORRA April 2013 to October 2018, follow-up through 2019, and participated ≥2 surveys. Index was defined as date first entry...
<h3>Background</h3> Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Improvements in patient-reported outcomes (PROs) have been reported global population Phase (P)2, P3 and long-term extension (LTE) tofacitinib studies. <h3>Objectives</h3> To explore effect on PROs Japanese patients (pts) with RA. <h3>Methods</h3> In this post hoc analysis, data from pts RA were obtained two 12-week randomised dose-finding P2 studies methotrexate (MTX) inadequate...